Multiple myeloma invasion of the central nervous system

被引:77
作者
Schluterman, KO
Fassas, ABT
Van Hemert, RL
Harik, SI
机构
[1] Univ Arkansas Med Sci, Dept Neurol, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
[3] Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA
关键词
D O I
10.1001/archneur.61.9.1423
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Although neurologic manifestations often complicate the course of patients with multiple myeloma (MM), direct central nervous system invasion is rare. Objective: To describe the neurologic symptoms and signs, imaging, cerebrospinal fluid findings, and the clinical course of patients with central nervous system myeloma invasion, all of whom had leptomeningeal myelomatosis. Design and Participants: Review of 23 patients with MM and leptomeningeal myelomatosis proven by malignant plasma cells in their cerebrospinal fluid. Setting: Tertiary-care university medical center. Results: Twenty-one patients had advanced-stage MM. Leptomeningeal myelomatosis was diagnosed up to 29 months (median, 13 months) after diagnosis of MM. Symptoms precipitating neurologic evaluation included manifestations of diffuse cerebral dysfunction, cranial nerve palsies, and spinal radiculopathies. Cerebrospinal fluid was abnormal in all patients, usually exhibiting pleocytosis and elevated protein content, plus positive cyto-logic findings. Specific magnetic resonance imaging findings suggestive of central nervous system invasion were found in 70% of the patients. These included leptomeningeal contrast enhancement and evidence of meningeal-based lesions sometimes masquerading as intraparenchymal lesions. Despite aggressive systemic and local treatment, the outcome was poor, reflecting the aggressiveness of the underlying MM. Conclusion: Leptomeningeal myelomatosis, although rare, should be considered in patients with MM and symptoms suggestive of widespread nervous system involvement.
引用
收藏
页码:1423 / 1429
页数:7
相关论文
共 25 条
[1]   High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions [J].
Badros, A ;
Barlogie, B ;
Morris, C ;
Desikan, R ;
Martin, SR ;
Munshi, N ;
Zangari, M ;
Toor, A ;
Cottler-Fox, M ;
Fassas, A ;
Aniassie, E ;
Schichman, S ;
Tricot, G .
BLOOD, 2001, 97 (09) :2574-2579
[2]   Total therapy with tandem transplants for newly diagnosed multiple myeloma [J].
Barlogie, B ;
Jagannath, S ;
Desikan, KR ;
Mattox, S ;
Vesole, D ;
Siegel, D ;
Tricot, G ;
Munshi, N ;
Fassas, A ;
Singhal, S ;
Mehta, J ;
Anaissie, E ;
Dhodapkar, D ;
Naucke, S ;
Cromer, J ;
Sawyer, J ;
Epstein, J ;
Spoon, D ;
Ayers, D ;
Cheson, B ;
Crowley, J .
BLOOD, 1999, 93 (01) :55-65
[3]  
BOOGERD W, 1991, CANCER, V67, P1685, DOI 10.1002/1097-0142(19910315)67:6<1685::AID-CNCR2820670635>3.0.CO
[4]  
2-M
[5]  
BUNN PA, 1976, BLOOD, V47, P3
[6]  
Cavanna L, 1996, ACTA CYTOL, V40, P571
[7]  
DELAFUENTE J, 1994, EUR J HAEMATOL, V53, P244
[8]   Myeloma of the central nervous system: Strong association with unfavorable chromosomal abnormalities and other high-risk disease features [J].
Fassas, ABT ;
Ward, S ;
Muwalla, F ;
Van Hemert, R ;
Schluterman, K ;
Harik, S ;
Tricot, G .
LEUKEMIA & LYMPHOMA, 2004, 45 (02) :291-300
[9]   Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations [J].
Fassas, ABT ;
Muwalla, F ;
Berryman, T ;
Benramdane, R ;
Joseph, L ;
Anaissie, E ;
Sethi, R ;
Desikan, R ;
Siegel, D ;
Badros, A ;
Toor, A ;
Zangari, M ;
Morris, C ;
Angtuaco, E ;
Mathew, S ;
Wilson, C ;
Hough, A ;
Harik, S ;
Barlogie, B ;
Tricot, G .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) :103-108
[10]   Leptomeningeal carcinomatosis [J].
Grossman, SA ;
Krabak, MJ .
CANCER TREATMENT REVIEWS, 1999, 25 (02) :103-119